Nuance Pharma: Building a Cash-Generating Powerhouse in Specialty Respiratory Therapeutics

In the course of China’s innovative drug reform, license-in has been an unavoidable topic. Among the many companies focusing on license-in deals for oncology and immunology projects, Yourui Pharmaceutical stands out for its unique focus on premium specialty drugs in the respiratory field, as well as in anemia and pain management.

As an innovation-driven biopharmaceutical company, Yourui Pharmaceutical has successfully built a globally leading pipeline of innovative drugs for respiratory diseases and established a mature portfolio of commercialized products in the fields of iron deficiency anemia and emergency care treatment, committed to effectively addressing critical unmet medical needs in the Asia-Pacific region. Expansion across the Asia-Pacific will position Yourui as a leader in achieving geographic diversification within China.

Yourui Pharmaceutical’s growth operations following the acquisition of Niferex, its successful merger with Zhongjian Pharmaceutical, and its licensing of novel drugs such as ensifentrine all demonstrate the formidable commercialization capabilities of this young pharmaceutical company.

Recently, VBInsight interviewed Mr. Mark Lotter, Founder and CEO of Yourui Pharmaceutical.Mark Lotter was one of AstraZeneca’s first executives to come to China,Over 20 years of market experience in China's healthcare industry.Mark Lotter shared with us how Yourui Pharmaceutical cultivated its cash-generating capabilities and gradually grew into a differentiated specialty pharmaceutical company.

China’s pharmaceutical policies and market have undergone significant changes since 2014, with the National Medical Products Administration (NMPA) leading reforms in the approval of innovative drugs, local governments introducing preferential policies to support startups, and the domestic license-in model gradually gaining prominence.

With the support of capital, a number of companies have rapidly introduced early-stage pipelines through the license-in model, and then leveraged China’s large patient population and mature CRO companies to accelerate clinical development and commercialization.

The value of focusing on license-in innovation lies in the fact that channel distribution and commercialization are also critical capabilities, representing a vital link in the pharmaceutical industry chain.

Having witnessed the development of China’s pharmaceutical market over the past two decades, Mr. Mark Lotter, Founder and CEO of Yourui Pharmaceutical, is well aware that target acquisitions represent a “deep-water” zone of intense competition. He frankly states that financial strength alone is insufficient for success in the license-in model. Yourui Pharmaceutical evaluates multiple dimensions: whether the price is appropriate, who the competing bidders are, whether the pipeline products possess sufficient innovation and R&D barriers, how competitive they are against products from other domestic companies and even multinational pharmaceutical firms, and what potential competitors may emerge in the same therapeutic area in the future.

Mr. Mark Lotter, Founder and CEO of Yourui Pharmaceutical

Leveraging extensive medical expertise and industry resources,Over the past few years, Yourui Pharmaceutical has steadily and precisely acquired multiple drug pipelines in specialized therapeutic areas, including iron-deficiency disorders, non-opioid analgesia, and respiratory diseases.Leveraging a pragmatic and robust sales team and an extensive channel platform, the company continues to increase product sales. It currently has five commercialized products. In the fields of respiratory diseases and pain management, Yourui Pharmaceutical also has five drug candidates in late-stage clinical development.

Yourui consistently and proactively “captures” leading global pipelines in development, successfully introducing first-in-class therapies to China through license-in commercial partnerships, while connecting top domestic academic experts with patient organizations to accelerate late-stage clinical development.

Chronic respiratory diseases are the second leading cause of death globally. Characterized by prolonged disease courses and impaired patient autonomy during exacerbations, coupled with limited therapeutic options, these conditions impose a substantial disease burden across all global economic systems. There is significant room for improvement in drug delivery methods and the introduction of novel treatment modalities.

The respiratory field in China is an undisputed blue ocean. Driven by factors such as deteriorating air quality, rising smoking rates, and deepening population aging, the incidence of diseases like chronic obstructive pulmonary disease (COPD) and asthma continues to climb. In 2022, the market size for respiratory diseases in China approached nearly $7 billion. Furthermore, viral respiratory illnesses—specifically those caused by respiratory syncytial virus (RSV)—and allergic conditions remain significant challenges for both patients and physicians.

In the evolution of respiratory chronic disease education in China—from a stage marked by insufficient awareness among physicians and patients and a scarcity of drug options to one characterized by the continuous emergence of innovative therapies and alignment with international standards—multinational pharmaceutical companies have played a pivotal leading role. For instance, AstraZeneca introduced respiratory therapies such as inhaled corticosteroids, bronchodilators, and nebulization treatments to the Chinese market. As one of AstraZeneca’s first senior executives in China, Mark Lotter, founder of Yourui Pharmaceutical Technology (Shanghai) Co., Ltd., spearheaded the development of AstraZeneca China’s early innovative strategy in the field of respiratory nebulization therapy.

Amid intensifying competition for license-in deals, few players have ventured into the respiratory field.Most companies have focused their attention on oncology, neuroscience, autoimmune diseases, and other fields. Due to high technical barriers and significant challenges in developing generics, global first-in-class therapies in the respiratory field are exceedingly rare. In the post-pandemic era, Chinese patients will demonstrate more proactive and clear-cut awareness of prevention and demand for treatment regarding respiratory diseases.

Immersed in the landscape, seasoned healthcare entrepreneurs like Mark Lotter are highly attuned to the challenges facing Chinese pharmaceutical companies as well as the accompanying opportunities, recognizing the importance and potential of the Chinese market.For example, as health insurance coverage deepens and out-of-pocket payment capacity strengthens, the penetration rate of specialty drugs will continue to rise; China has 50 million asthma patients, 100 million COPD patients, and 250 million patients with allergic rhinitis; and so on.

Yourui expands its focus areas by enriching treatment options for respiratory diseases, thereby addressing these unmet medical needs through its product portfolio.

Currently, Yourui Pharmaceutical is focused on building a globally leading late-stage clinical pipeline in respiratory diseases, including chronic obstructive pulmonary disease (COPD), respiratory syncytial virus (RSV) vaccines, neonatal respiratory distress syndrome, and allergic rhinitis, and has two First-in-Class candidate therapeutics.

Among them is Ensifentrine, a novel dual PDE3/PDE4 inhibitor that has made remarkable progress among investigational drugs for the treatment of COPD. Currently, mainstream therapies for COPD in China primarily include long-acting anticholinergics, long-acting β2-agonists, and inhaled corticosteroids; however, these treatments have limited impact on disease progression or mortality. By leveraging a dual inhibition mechanism, Ensifentrine achieves both bronchodilation and anti-inflammatory effects with a single compound, holding significant potential to become a first-in-class global therapy for patients with COPD in China.

Just last year, Yourui Pharmaceutical entered into a strategic partnership with Verona Pharma, successfully securing exclusive rights to develop and commercialize Ensifentrine in Greater China. Yourui rapidly advanced the domestic R&D process, with its Phase III clinical trial application in China approved within a matter of months. The ENHANCE-CHINA trial will be led by China’s top academic experts in the field of respiratory medicine.

Ensifentrine is a flagship asset in Yourui’s pipeline: a global first-in-class therapy with “blockbuster” potential, effectively addressing the vast potential of China’s respiratory market, offering a competitive advantage over peers, and backed by R&D support from key opinion leaders.

However, for specialty pharmaceutical companies focused on premium products, acquiring a pipeline is merely the beginning; the more critical challenge lies in maximizing the value of the acquired pipeline. In this regard, Yourui also boasts extensive experience.

Yourui Pharmaceutical’s first commercialized product is Liferran, acquired in 2019. As the only fully imported polysaccharide iron supplement on the market, Liferran has been used in clinical practice in China for over two decades and has gained a certain level of recognition. Prior to its divestiture by UCB, sales remained relatively stable but showed insignificant growth.

Yourui believes that Lifeneo targets a broad patient population, including children, pregnant women, renal patients with iron deficiency and ischemia due to dialysis, and individuals in postoperative recovery, making it well-suited for continued expansion in the consumer (to-C) sector. As an imported product, Lifeneo also holds significant advantages in quality. Therefore, it presents multiple possibilities for growth.

Following the acquisition of Niferex, Yourui has been gradually upgrading its product portfolio, aiming to offer a wider range of new formulations, such as sustained-release and powder forms. The company also plans to launch other health supplements, including vitamin C and folic acid, to meet market demand. In terms of distribution channels, it covers hospitals, retail pharmacies, and e-commerce platforms such as JD.com and Ali Health, while simultaneously expanding into regional markets by launching Niferex as a nutritional preparation in Asia-Pacific countries.

Through a three-pronged approach, Lifeiron achieved double-digit growth under the operation of Yourui Pharmaceutical Technology (Shanghai) Co., Ltd., with annual sales reaching approximately RMB 300 million in 2021.

In addition to licensing or acquiring individual pipelines, Yourui Pharmaceutical has also demonstrated outstanding capabilities in mergers and acquisitions integration. In 2021, Yourui fully acquired Zhongjian Pharmaceutical, obtaining three mature products in the emergency care sector, including Isosorbide Dinitrate and Isosorbide Mononitrate.

Integrated into Yourui Pharmaceutical along with the products was Zhongjian Pharmaceutical’s mature sales system, whose distribution network covers approximately 3,500 hospitals and 6,500 pharmacies across 29 provinces. This acquisition not only helped Yourui expand its business into the ICU and cardiovascular therapeutic areas but also significantly enhanced its market coverage and distribution capabilities.

Evergreen products that continuously generate new growth drivers to fuel robust revenue growth, thereby sustaining R&D for Phase III clinical pipeline candidates and ensuring more efficient post-launch growth, have formed Yourui Pharmaceutical’s unique dual-engine model of “commercial marketing + collaborative R&D,” which has been proven effective through several years of commercial operations.

In summary,Establishing market-oriented products and pipelines for China and its managed regions requires several core capabilities, including:Business development and R&D—a multinational corporation-like structure has been implemented, with substantial progress made in the regulatory submissions filed in 2022. Finally, regarding commercialization, the company excels at leveraging and developing acquired legacy assets while possessing the capability to launch new products into the market.

The capital market has shown strong recognition of Yourui Pharmaceutical’s execution capabilities and strategic foresight. In addition to MPCi, Yourui has successively secured financial support and resource synergies from a diverse group of investors, including CBC Group, China Reform Guoxin Fund, and Kangchen Pharmaceutical, completing a $180 million Series D financing round by the end of 2020. Commercial partners Verona Pharma and Aerogen Pharma have also subscribed to equity stakes in Yourui, demonstrating their confidence in the company.

The achievement of milestones in business development, pipeline construction, and research and development within just three years is inseparable from the diverse leadership team at Yourui Pharmaceutical. Core members hailing from industry leaders such as AstraZeneca, WuXi AppTec, McKinsey, and Bristol Myers Squibb bring specialized expertise and multiple professional perspectives to the company.

It is understood that Yourui Pharmaceutical is also pursuing a global strategy. In 2022, leveraging its international supply chain and commercial partnership network, the company officially launched its business expansion in the Asia-Pacific region, starting from the Hong Kong market.

We believe that this team, with its innate global perspective, will accelerate its expansion into the vast Asia-Pacific region, driven by its “dual-wheel model” and internationalization strategy.